A Global Study of the PETAL Consortium
Part of paid clinical trials in Duarte, California.
- Sponsor
- Massachusetts General Hospital
- Study ID
- NCT06067347
- Status
- Recruiting
Conditions
- T-Cell and NK-Cell Neoplasm
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Accepted
Study Details
The goal of this observational study is to correlate molecular alterations with outcomes including overall survival (OS), progression-free survival (PFS), response rates for patients with a new diagnosis, primary refractory or relapse, of mature T-cell and NK-cell neoplasms (TNKL). We hypothesize that machine learning can be leveraged to uncover distinct genetic vulnerabilities that underlie treatment response and resistance for patients with TNKL, thus moving towards personalized treatment solutions.
Key Dates
- Start date
- Jan 5, 2024
- Status verified
- Apr 2026
- Primary completion
- Jan 31, 2028
- Completion
- Jan 31, 2028
Study Design
- Enrollment
- 1,200 participants (estimated)
Arms
- Arm: Massachusetts General Hospital, Boston, USAParticipating investigators at various institutions will perform weekly review of their new patients with PTCL (newly diagnosed or relapsed/refractory) on the outpatient and inpatient clinical services with their clinical research teams to identify potential subjects for enrollment based on the above inclusion/exclusion criteria. Expected enrollment is anticipated to be up to 50 patients per site per year.
Primary Outcome Measure
Overall Survival [ Time Frame: Up to 4 Years ]
Central Contacts
- Salvia Jain, MD650-224-0183
- Forum Bhanushali857-757-0966
Locations (10)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| City of Hope | Duarte | California | 91010 | Christina Poh, MD (PRINCIPAL_INVESTIGATOR) |
| University of Colorado | Denver | Colorado | 80204 | (303) 315-5969 Bradley Haverkos, MD (PRINCIPAL_INVESTIGATOR) |
| Moffitt Cancer Center | Tampa | Florida | 33612 | Yumeng Zhang, MD (PRINCIPAL_INVESTIGATOR) |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | Eric Jacobsen, MD (PRINCIPAL_INVESTIGATOR) |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | Salvia Jain, MD (PRINCIPAL_INVESTIGATOR) |
| Mayo Clinic | Rochester | Minnesota | 55905 | Bennani Nora, MD (PRINCIPAL_INVESTIGATOR) |
| Hackensack University Medical Center | Hackensack | New Jersey | 07601 | Tatyana Feldman, MD (PRINCIPAL_INVESTIGATOR) |
| OhioHealth | Columbus | Ohio | 43214 | Basem William, MD (PRINCIPAL_INVESTIGATOR) |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | Stefan Barta, MD (PRINCIPAL_INVESTIGATOR) |
| University of Virginia | Charlottesville | Virginia | 22903-4 | Enrica Marchi, MD (PRINCIPAL_INVESTIGATOR) |